Subtitle: Market Intelligence, Synthetic Lethality Programs, and High-Purity Reagents for COPI-Targeted Cancer Therapy Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for COPZ1 drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | COPZ1 Recombinant Protein (Full-length) High purity (>95%), Endotoxin <1 EU/µg. Sequence Verified. E. coli / HEK293 expressed. |
View COPZ1 Products |
| Gene Delivery | COPZ1 Promise-ORF / Lentivirus Full-length ORF for stable cell lines and CRISPR rescue experiments. |
View COPZ1 Products |
| Benchmark Ab | Anti-COPZ1 (Sequence Verified Clone) Recombinant monoclonal antibody for detection, pulldown, and degradation assays. |
View COPZ1 Products |
| Validator | COPZ1 siRNA Set (3 unique sequences) For synthetic lethality knockdown verification and specificity controls. |
View COPZ1 Products |
| Related Target A | COPB2 Core COPI subunit; essential for coatomer complex assembly and retrograde transport synergy. |
View COPB2 Products |
| Related Target B | COPZ2 Critical paralog for synthetic lethality counter-screening in COPZ2-deficient contexts. |
View COPZ2 Products |
| Related Target C | COPA Direct binding partner of COPZ1; alpha subunit of COPI complex; counter-screening essential. |
View COPA Products |
| Related Target D | ARF1 Upstream GTPase recruiting COPI to Golgi membranes; regulatory node for COPI function. |
View ARF1 Products |
| Related Target E | ARID1A (BAF250A) Synthetic lethal context marker; chromatin remodeling deficiency indicator. |
View ARID1A Products |
| Related Target F | SEC23A / SEC23B COPII pathway components for off-target toxicity counter-screening. |
View SEC23A Products |
Critical Assay Challenges & Technical Specifications
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| COPI complex assembly and PPI mapping | Human COPZ1 recombinant protein >95% purity, endotoxin controlled, suitable for SPR/BLI; mass spec verified. |
| Synthetic lethality validation in PTEN-null / ARID1A-mutant models | COPZ1 Lentivirus ORF and shRNA particles for rescue and knockdown experiments; isogenic cell line compatible. |
| COPZ1 vs COPZ2 selectivity screening | High-purity homologous proteins (COPZ1 & COPZ2) strictly verified by mass spec for accurate SPR/BLI counter-screening. |
| Intracellular target engagement for PROTACs | Native conformation and theoretical MW confirmed recombinant proteins for optimized ternary complex assays. |
| Cross-species evaluation (mouse / cyno) | Human / Mouse / Cyno ortholog proteins available with sequence verification. |
| Off-target toxicity screening (COPII pathway distinction) | SEC23A/B proteins available for counter-screening; sequence-verified distinct epitopes. |
| Cellular phenotype false positives | Validated siRNA sets included for precise target specificity and viability checks. |
Live COPZ1 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The therapeutic potential of COPZ1 lies in its essential role within the COPI machinery governing retrograde Golgi-to-ER transport. As a synthetic lethal target, COPZ1 inhibition shows promise in multiple genetic contexts: PTEN-null solid tumors (e.g., colorectal cancer), COPZ2-deficient cancers (thyroid, breast, ovarian), and ARID1A-mutant tumors (ovarian, endometrial, gastric). These contexts share a heightened dependence on vesicular trafficking. The current R&D landscape is dominated by early-stage discovery programs focusing on small-molecule disruption of COPI subunit interactions (including molecular glues), PROTAC-mediated degradation, and RNAi-based approaches. Major players include academic consortia (Broad Institute, Wellcome Sanger) and emerging biotechs specializing in synthetic lethality. As first-generation screens validate COPZ1 dependency, the next wave targets subunit-specific modulation to minimize toxicity associated with general COPI disruption. Future trends include combination therapies with ER stress inducers or autophagy inhibitors, and the development of companion diagnostics for biomarker-driven patient selection.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule Inhibitors / Molecular Glue | Emerging synthetic lethality biotechs; Academic consortia | PTEN-null solid tumors, Colorectal cancer, ARID1A-mutant ovarian/endometrial | PPI Disruption Assay (Need high-purity COPZ1 + COPB2/COPA recombinant proteins for SPR/BLI) |
| PROTACs / Degraders | Academic Consortia; Startup Pharma | Refractory thyroid, ovarian, breast cancers (COPZ2-deficient) | Ternary Complex Validation (Need sequence-verified target antigens and benchmark antibodies) |
| RNAi / siRNA / shRNA | Functional genomics platforms; Preclinical gene therapy firms | Oncology dependency mapping; Metastatic breast cancer | Knockdown Validation (Need validated siRNA and rescue ORF lentivirus) |
| Genetic Screens (CRISPR) | Academic research; Preclinical | ARID1A-mutant solid tumors | Isogenic cell line tools; lentivirus rescue constructs |